What are the historical ranges of flu vaccine effectiveness in H3N2-dominant seasons and how do they compare to 2025–26?
Executive summary
H3N2-dominant seasons have historically delivered lower and more variable influenza vaccine effectiveness (VE) than other seasons, with broad typical VE ranges around 30%–60% depending on age group and outcome (outpatient illness vs hospitalization) [1] [2]. Early real-world estimates for the 2025–26 season—collected during the rise of the H3N2 subclade K—show substantial protection against severe outcomes in children (≈72–75% for ED attendance/hospitalization) but only modest protection in adults (≈32–40% for the same endpoints), placing 2025–26 within the historical pattern of lower VE in H3N2 years while also showing stronger pediatric performance than many past H3N2-dominant seasons [3] [4] [5] [1].
1. Historical patterns: H3N2 seasons trend toward lower, age‑dependent VE
Public-health summaries and reviews note that vaccine performance varies year to year but "typically falls between 30% and 60%," and that H3N2-dominant seasons tend to sit toward the lower end of that range with more severe outcomes in older adults and young children [1] [2] [5]. CDC archives and effectiveness tables document wide variability across seasons and by endpoint (outpatient illness, medically attended illness, hospitalization), reflecting recurrent antigenic drift in H3N2 viruses and technical issues (egg adaptation for some vaccines) that have historically depressed VE [6] [7].
2. Why H3N2 yields lower VE: virology and vaccine‑match mechanics
H3N2 viruses mutate rapidly in the hemagglutinin protein and frequently accumulate substitutions that reduce recognition by vaccine-induced antibodies; those antigenic shifts plus vaccine production differences (egg-adapted vs cell/recombinant strains) help explain why H3N2 seasons regularly produce lower VE than H1N1 or well-matched B seasons [8] [7] [2]. Public-health agencies explicitly warn that antigenic drift—like the emergence of subclade K—can lower individual and population-level immunity and thus reduce annual VE [5] [8].
3. The 2025–26 picture: subclade K, early data, and headline numbers
Early 2025–26 surveillance found subclade K (an H3N2 branch) rising rapidly and diverging genetically from the vaccine's reference viruses, and antigenic assays with ferret antisera showed reduced reactivity to subclade K—signalizing imperfect match potential [3] [8]. Real-world early VE estimates from England’s preprint and corroborating summaries show VE of about 72–75% against emergency department attendance and hospital admission in those under 18, and about 32–39% (rounded in journalism to ~30–40%) in adults for those same severe outcomes [3] [4] [5]. These early metrics place the overall adult VE at the lower historic H3N2 range while pediatric VE appears higher than often-seen H3N2 performance [3] [1].
4. Context, caveats, and why early season VE can shift
Early-season VE estimates are preliminary and depend on circulating mix, age-specific immunity, the clinical endpoint measured (medical visits vs hospitalization), and geographic differences in subclade prevalence; agencies caution that dominance of H3N2/subclade K through the whole season is not certain and VE may change as the season evolves [8] [9] [5]. Surveillance gaps, differences in study design across countries, and the distinction between protection against infection versus severe outcomes all mean headline VE numbers should be interpreted within those constraints [9] [6].
5. How 2025–26 compares to past H3N2 peaks—similarities and notable differences
Qualitatively, 2025–26 fits the historical pattern of reduced VE in H3N2 years—adult VE estimates in the low‑to‑mid 30% range are within previously observed low H3N2 seasons—yet the strong pediatric protection (≈72–75% against severe outcomes) is comparatively higher than some prior H3N2 years and may reflect vaccine performance by age or other epidemiologic factors [1] [3] [2]. Public-health messaging therefore balances two truths: the vaccine is less protective against H3N2 infection than in some seasons, but it still provides meaningful protection against severe disease—especially among children—so vaccination remains the recommended mitigation [5] [10].
6. The narrative around "mismatch" and incentives in coverage
Media and advocacy headlines that frame subclade K as a "superflu" risk overstating novelty; several public-health sources urge nuance, noting antigenic divergence but also evidence of retained protection against severe outcomes and absence of antiviral resistance signals so far—this mix of alarm and reassurance reveals competing incentives in coverage: urgency to drive uptake versus the need to avoid exaggerated panic [1] [11] [3]. Surveillance and peer-reviewed VE studies across different countries and endpoints will be essential to finalize how 2025–26 stacks up in the H3N2 historical record [9] [6].